Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine.
Clare P HerdClaire L TomlinsonCaroline RickWilliam J ScottonJulie EdwardsNatalie J IvesCarl E ClarkeA J SinclairPublished in: BMJ open (2019)
In chronic migraine, botulinum toxin reduces migraine frequency by 2 days/month and has a favourable safety profile. Inclusion of medication overuse headache does not preclude its effectiveness. Evidence to support or refute efficacy in episodic migraine was not identified.